💉 Eli Lilly on a buyout spree; Sanofi optimistic about vaccine sales; Aurobindo Pharma’s quality lapses

#374 | Giving up on sugar substitutes; Predicting type 1 diabetes; Enabling AMR with microplastics

Hello and welcome to The Friday Kable, where we continue to hate on sugar substitutes, Indian pharma manufacturers continue to mess up, and semaglutide continues to prove its appeal.

But first, some Big Pharma updates. Eli Lilly is acquiring the cell therapy developer Sigilon Therapeutics for an upfront payment of a little under $35 million. The two comp…